Authors
Latest:
Dr. Harbeck on the Background of the WSG ADAPT-TP Trial in HR+, HER2+ Breast CancerNadia Harbeck, MD, PhD, discusses the background of the phase 2 WSG ADAPT-TP trial in hormone receptor-positive, HER2-positive early-stage breast cancer.
Latest:
Dr Giles on the Importance of Shared Decision Making When Managing GU CancersRachel Giles, MD, PhD, discusses the importance of incorporating shared decision making in the treatment of patients with genitourinary cancers.
Latest:
Dr. Jasmine Zain: Challenges in T-Cell Lymphoma TreatmentJasmine Zain, MD, director of the T-cell Lymphoma Program, professor of hematology and hematopoietic stem cell transplantation, of City of Hope National Medical Center, discusses the challenges of treatment for patients with T-cell lymphoma.
Latest:
Dr DeBernardo on an Ovarian Cancer Patient Case StudyRobert DeBernardo, MD, discusses a case study seen in a patient with ovarian cancer.
Latest:
Dr Muslimani on Unanswered Questions to be Addressed in HER2+ mCRCAlaa Muslimani, MD, discusses unanswered questions in the treatment of patients with metastatic colorectal cancer, highlighting how these unmet needs may be addressed through continued research.
Latest:
Dr. Khushman on Best Practices in the Management of GI CancersMoh’d Khushman, MD, discusses best practices in the management of gastrointestinal cancers.
Latest:
Palliative Care Can Address Gaps in Oncology LandscapePalliative medicine has evolved to become a standard for high-quality cancer care, helping patients relieve suffering throughout their journey, improving quality of life, and prolonging survivorship.
Latest:
FDA Panel Gives Beti-Cel Unanimous Support of Benefit in β-thalassemiaThe FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee voted unanimously in favor of the benefit of betibeglogene autotemcel for the treatment of transfusion-dependent β-thalassemia in adult and pediatric patients with a non–β0/β0 genotype.
Latest:
Kevin Hakimi on the Rationale of the PADRES Trial in RCCKevin Hakimi, discusses the rationale for the phase 2 PADRES trial in clear cell renal cell carcinoma.
Latest:
Unmet Needs and Future Perspectives in Colorectal CancerThe panel concludes with perspectives on the future of treatment for patients with colorectal cancer, including unmet needs in the disease space.
Latest:
Dr Stone on the Investigation of Limited English Proficiency and PSA Screening Rates in Prostate CancerBenjamin V. Stone, MD, discusses clinical implications derived from a retrospective study on the effect of limited English proficiency on prostate-specific antigen screening rates in American men with prostate cancer, as well as the need to improve equitable access to PSA screening across academic and community centers.
Latest:
Renal Cell Carcinoma: Future Directions in CareLooking toward the future management of renal cell carcinoma, experts consider treatment strategies for bone metastasis, brain metastasis, and VHL disease.
Latest:
Immunotherapy for NSCLC: Clinical PearlsFinal takeaways from ASCO 2021 and the use of immunotherapy to treat various types of patients with non–small cell lung cancer.
Latest:
Dr. LeBeau on the Potential Applicability of Shark Antibodies in Prostate CancerAaron LeBeau, PhD, discusses the potential wide applicability of shark antibodies in developing imaging and therapeutic strategies in prostate cancer.
Latest:
Dr Nieva on the Rationale for Investigating At-Home Atezolizumab Administration in NSCLCJorge Nieva, MD, discusses the rationale and design of an ongoing phase 2 trial investigating a telemedicine approach to delivering subcutaneous atezolizumab for patients with non–small cell lung cancer.
Latest:
Dr. Bachelot on the Role of Tucatinib in HER2+ Breast Cancer With CNS MetastasesThomas Bachelot, MD, PhD, discusses the role of the combination of tucatinib plus trastuzumab and capecitabine in patients with HER2-positive breast cancer who have central nervous system metastases.
Latest:
Dr. O’Regan on the Development of Oral SERDs in Breast CancerRuth M. O’Regan, MD, discusses the development of oral selective estrogen receptor degraders in hormone receptor–positive breast cancer.
Latest:
Overcoming Barriers to Molecular Testing in NSCLC With Multidisciplinary CareA brief discussion on key barriers to molecular testing in non–small cell lung cancer and how multidisciplinary care plays a role in addressing these hurdles.
Latest:
Dr Muzaffar on the Evaluation of FLX475 Plus Pembrolizumab in HNSCCJameel Muzaffar, MD, discusses a study of FLX475 plus pembrolizumab in patients with head and neck squamous cell carcinoma.
Latest:
What’s Coming Next in Relapsed/Refractory Multiple MyelomaKey opinion leaders remark about recently approved therapies and exciting future treatment options for relapsed/refractory multiple myeloma.
Latest:
Dr. Boutros on the Utility of Genetic Testing in Prostate CancerPaul C. Boutros, PhD, MBA, discusses the utility of genetic testing in prostate cancer.
Latest:
Dr Iglesia on the COSMIC-312 Trial of Cabozantinib Plus Atezolizumab in HCCMichael Iglesia, MD, PhD, discusses outcomes from the phase 3 COSMIC-312 trial of first-line cabozantinib plus atezolizumab in hepatocellular carcinoma.
Latest:
Dr. Uy on the Efficacy Findings from a Phase 1/2 Trial in R/R AMLGeoffrey L. Uy, MD, discusses the efficacy findings from a phase 1/2 trial in relapsed/refractory acute myeloid leukemia.
Latest:
Closing Thoughts on the MDS Treatment LandscapeFollowing its comprehensive discussion on the treatment of MDS, the expert panel concludes with thoughts on the overall treatment landscape.
Latest:
Dr. Markowski on the Evaluation of Sabizabulin in mCRPCMark C. Markowski, MD, PhD, discusses the evaluation of sabizabulin in a phase 1b/2 trial in metastatic castration-resistant prostate cancer.
Latest:
AML, ALL, and Glioblastoma Multiforme Clinical Trials Seek to Push the Needle ForwardLeland Metheny, MD, discusses how agents such as Iomab-B have potential to shift practice in the hematologic malignancy space.
Latest:
Dr. Ghodoussipour on Trials of Cytoreductive Surgery in Metastatic RCC and Prostate CancerSaum Ghodoussipour, MD, discusses ongoing trials in renal cell carcinoma and prostate cancer.
Latest:
Treatment Option for Adult Patients with 3L+ Relapsed or Refractory Diffuse Large B-Cell LymphomaMany people living with diffuse large B-cell lymphoma (DLBCL) continue to experience significant treatment challenges. Genmab and AbbVie discuss the current DLBCL treatment landscape and an effort as part of a collaboration between the two companies for people diagnosed with relapsed or refractory DLBCL.
